Bluejay Diagnostics (BJDX) Equity Ratio (2020 - 2026)

Bluejay Diagnostics has disclosed Equity Ratio across 7 years of filings, most recently posting 0.75 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.75, up 1.95% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.75 (up 1.95% YoY), and the FY2025 annual result was 0.84, down 2.48% from the prior year.
• Equity Ratio came in at 0.75 for Q1 2026 at Bluejay Diagnostics, down from 0.84 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.92 in Q2 2022 to a low of 0.59 in Q4 2023.
• The 5-year median for Equity Ratio is 0.83 (2025), against an average of 0.79.
• Across the five-year window, Equity Ratio surged 394.72% in 2022 and slumped 30.34% in 2023, its largest moves.
• Bluejay Diagnostics' Equity Ratio stood at 0.85 in 2022, then tumbled by 30.34% to 0.59 in 2023, then soared by 44.74% to 0.86 in 2024, then fell by 2.48% to 0.84 in 2025, then dropped by 11.02% to 0.75 in 2026.
• The last three Equity Ratio figures came in at 0.75 (Q1 2026), 0.84 (Q4 2025), and 0.76 (Q3 2025), per Business Quant data.